科美診斷(688468.SH)一度大漲超16% 領漲板塊
格隆匯5月17日丨醫療保健設備股集體走強,其中,次新股科美診斷(688468.SH)盤中一度漲16.29%報26.98元,領漲板塊,市值108億元。據悉,科美診斷是國內領先的光激化學發光免疫診斷企業,公司產品在傳染病檢測、腫瘤標誌物檢測領域檢測性能與國際第一梯隊企業產品具有高度一致性,進口替代空間廣闊。公司營銷網絡覆蓋全國,單機產出達30萬,高於行業競爭對手。公司4月底公佈的業績顯示,2021年一季度營收1.20億元,同比增103.52%;歸屬上市公司股東的扣非淨利潤3663萬元,同比增793.42%。基於對產品開發的精益求精和對市場需求的精準把握,LiCA系列產品對公司整體收入提振顯着。科美診斷表示,一季度營收大幅增長主要系LiCA系列產品銷量增加所致。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.